A new randomized, placebo-controlled clinical study adds further scientific support for BODYBALANCE® Bioactive Collagen Peptides, GELITA’s targeted ingredient solution for innovative sports nutrition and active lifestyle products.
Published in Frontiers in Physiology, the study is the first of its kind to systematically examine subtype-specific intramuscular collagen adaptations – types I, III and IV – in response to long-term collagen supplementation during resistance training in humans. The results show that daily supplementation with BODYBALANCE® Bioactive Collagen Peptides, combined with 12 weeks of high-load resistance training, led to a significantly greater increase in endomysial collagen type I content than training with placebo. Collagen type I is an important structural component within muscle tissue and contributes to the extracellular matrix that supports skeletal myofibers.
In the trial, 29 healthy male participants consumed either 15 g per day of specific collagen peptides or a placebo while following a structured resistance training program. The BODYBALANCE® group achieved a 29.8% increase in endomysial collagen type I content, compared with 9.9% in the placebo group – an approximately 3.5-fold greater increase.
For manufacturers, BODYBALANCE® offers a science-backed way to develop differentiated products for active consumers – from powders and ready-to-drink beverages to bars, shots and functional foods. With its strong scientific foundation and high formulation flexibility, BODYBALANCE® helps brands create sports nutrition concepts that go beyond conventional protein positioning.
With these latest findings, BODYBALANCE® continues to strengthen its position as a trusted Bioactive Collagen Peptides solution for forward-looking sports nutrition innovation. The GELITA LifeScience Institute is your expert partner, providing scientific expertise and application know-how to support the development of your next differentiated product concept.